Biointron Insights: Antibody Industry Outlook (2026 Insights, Trends & Analysis)

Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends of the biopharmaceutical industry for 2026. Last year, 21 novel monoclonal antibody drugs were approved by China, the United States, Europe, and Australia.

1. Recaticimab (艾心安)

2. Vilobelimab (Gohibic)

3. Garadacimab (Andembry)

4. Finotonlimab (新替妥)

5. Siltartoxatug (Sintetol)

6. Sipavibart (Kavigale)

7. Ebdarokimab

8. Linvoseltamab (Lynozyfic)

9. Nipocalimab (Imaavy)

10. Telisotuzumab Vedotin (Emrelis)

11. Teprotumumab N01 (Sycume)

12. Trastuzumab Rezetecan

13. Clesrovimab (Enflonsia)

14. Suvemcitug (Enzheshu)

15. Firsekibart (Jin Beixin)

16. Becotatug Vedotin (美佑恒)

17. Trastuzumab Botidotin

18. Sibeprenlimab (Voyxact)

19. Picankibart (Pecondle)

20. Depemokimab (Exdensur)

21. Narsoplimab (Yartemlea)

2025 saw several large collaborations and acquisitions of up to USD$12 billion in value, primarily for bispecific antibody assets. Investment in antibody drug startups focused heavily on the use of artificial intelligence (AI) and antibody conjugates.

Gain exclusive insights into current trends such as:

• 21 novel antibody drugs approved for the first time in 2025 globally and comparison of disease focus areas of the past few years

• Top 10 biopharmaceutical companies by revenue and top-selling antibody drug

• A list of antibody therapeutics with soon approaching approval action dates or positive topline results to watch in 2026

• Top 10 antibody drug deals and startup debuts, including acquisitions, licensing agreements, and collaborations of up to US$12B

• The current antibody drug market size and predictions of future trends